- |||||||||| rivaroxaban / Generic mfg.
Clinical, Journal: Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. (Pubmed Central) - Oct 23, 2018 P3 Conclusions Rivaroxaban at a dose of 2.5 mg twice daily was not associated with a significantly lower rate of death, myocardial infarction, or stroke than placebo among patients with worsening chronic heart failure, reduced left ventricular ejection fraction, coronary artery disease, and no atrial fibrillation. (Funded by Janssen Research and Development; COMMANDER HF ClinicalTrials.gov number, NCT01877915 .).
- |||||||||| Xarelto (rivaroxaban) / J&J
Trial completion date, Trial primary completion date: XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (clinicaltrials.gov) - Sep 27, 2018 P4, N=10, Terminated, N=150 --> 84 | Trial completion date: Jan 2018 --> Mar 2019 | Trial primary completion date: Jan 2017 --> Dec 2018 Trial completion date: Dec 2017 --> Jun 2016 | Trial primary completion date: Jun 2017 --> Jun 2016
- |||||||||| Enrollment closed, Enrollment change: AtriClip (clinicaltrials.gov) - Sep 25, 2018
P4, N=562, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=2000 --> 562
- |||||||||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Clinical, Journal, HEOR, Real-world evidence: Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for nonvalvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. (Pubmed Central) - Sep 19, 2018 This study demonstrated a significantly higher risk of hospitalization (all-cause, stroke/SE, and major bleeding) associated with warfarin, a significantly higher risk of major bleeding hospitalization associated with dabigatran or rivaroxaban, and a significantly higher risk of all-cause hospitalization associated with rivaroxaban compared to apixaban. Lower major bleeding-related costs were observed for apixaban patients compared to warfarin and rivaroxaban patients.
- |||||||||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
Phase classification, Enrollment change, Trial primary completion date: Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) (clinicaltrials.gov) - Sep 14, 2018 P=N/A, N=600, Recruiting, In routine practice, the effectiveness and safety of rivaroxaban versus warfarin in VTE patients with a known PHS appears to be similar to that observed in the EINSTEIN trial program. Phase classification: P4 --> P=N/A | N=1600 --> 600 | Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Xarelto (rivaroxaban) / J&J
Enrollment closed, Surgery: Utilization of TEG to Monitor Rivaroxaban Activity (clinicaltrials.gov) - Sep 11, 2018 P=N/A, N=100, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Clinical, Review, Journal: Antithrombotic therapy for patients with STEMI undergoing primary PCI. (Pubmed Central) - Aug 31, 2018
Prasugrel and ticagrelor provide a more prompt, potent, and predictable antiplatelet effect compared with clopidogrel, which translates into better clinical outcomes...Thrombin has an important role, suggesting the need for strategies directly targeting circulating thrombin or other factors of the coagulation cascade, such as oral anticoagulants (rivaroxaban), and the thrombin receptor on the platelet membrane (vorapaxar). In this Review, we provide an overview of currently available antithrombotic therapies used in patients with STEMI undergoing PPCI, results from pivotal clinical trials and their implications for guidelines, as well as recommendations for clinical practice.
- |||||||||| Savaysa (edoxaban) / Daiichi Sankyo
Trial completion date, Trial primary completion date: Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis (clinicaltrials.gov) - Aug 28, 2018 P=N/A, N=56, Recruiting, The study population encompasses a broad array of patients across multiple continents and these subgroups provide ample opportunities for future research. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||||||||| rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo, Fragmin (dalteparin sodium) / Pfizer, Eisai
Review, Journal: The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. (Pubmed Central) - Aug 18, 2018 Many such studies are currently underway. The available data for the use of DOACs in the treatment of cancer-associated VTE will be reviewed, focusing on efficacy, safety, and other considerations relevant to the cancer patient.
- |||||||||| Savaysa (edoxaban) / Daiichi Sankyo
Enrollment open, Preclinical, Trial completion date, Trial initiation date, Trial primary completion date: PADOASU: In Vitro Diagnostic Test for DOAC in Urine (clinicaltrials.gov) - Aug 15, 2018 P=N/A, N=880, Recruiting, The available data for the use of DOACs in the treatment of cancer-associated VTE will be reviewed, focusing on efficacy, safety, and other considerations relevant to the cancer patient. Not yet recruiting --> Recruiting | Trial completion date: Mar 2018 --> May 2019 | Trial primary completion date: Dec 2017 --> Mar 2019 | Initiation date: Sep 2017 --> Aug 2018
- |||||||||| Ciraparantag (aripazine) / Norgine, Covis Pharma
Trial completion date, Trial primary completion date: Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT (clinicaltrials.gov) - Aug 8, 2018 P2, N=48, Recruiting, Active, not recruiting --> Completed Trial completion date: Jul 2018 --> Oct 2018 | Trial primary completion date: Jul 2018 --> Oct 2018
- |||||||||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial completion, Trial primary completion date: Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium (clinicaltrials.gov) - Aug 6, 2018 P4, N=110, Completed, The primary safety objective is to assess major bleeding events (Clinical trial information: NCT02555878). Recruiting --> Completed | Trial primary completion date: Nov 2017 --> Apr 2018
- |||||||||| Xarelto (rivaroxaban) / J&J
Trial completion date, Trial primary completion date: SECRET: Study of Rivaroxaban for CeREbral Venous Thrombosis (clinicaltrials.gov) - Aug 3, 2018 P2, N=380, Not yet recruiting, Active, not recruiting --> Completed Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- |||||||||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Review, Journal: Extended anticoagulation for unprovoked venous thromboembolism. (Pubmed Central) - Jul 28, 2018 This review article summarizes the evidence available for Vitamin-K antagonists (VKAs) and direct oral anticoagulants (DOACs) for extended treatment of VTE. We also introduce the COVET trial, the first head-to-head comparison of VKAs to DOACs, rivaroxaban and apixaban, for extended management of unprovoked VTE.
|